Overview

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer

Status:
Completed

Trial end date:
2007-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare treatment with oxaliplatin/5-FU/leucovorin plus vatalanib versus oxaliplatin/5-FU/leucovorin plus placebo in patients with colorectal cancer that has spread to other organs and whose disease has worsened after treatment with irinotecan.

Phase:

Phase 3

Details

Lead Sponsor:

Novartis Pharmaceuticals

Collaborator:

Bayer

Treatments:

Oxaliplatin
Vatalanib